These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 16831090)

  • 1. Dynamics of T cells subsets and lymphoproliferative responses during structured treatment interruption cycles and after definitive interruption of HAART in early chronic HIV type-1-infected patients.
    Libois A; López A; Garcia F; Castro P; Maleno MJ; García A; Climent N; Arnedo M; Gallart T; Gatell JM; Plana M
    AIDS Res Hum Retroviruses; 2006 Jul; 22(7):657-66. PubMed ID: 16831090
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of CD8+ T lymphocyte subsets with the most commonly used markers to monitor HIV type 1 infection in children treated with highly active antiretroviral therapy.
    Navarro J; Resino S; Bellón JM; Abad ML; Gurbindo D; Fernández-Cruz E; Muñóz-Fernández MA
    AIDS Res Hum Retroviruses; 2001 Apr; 17(6):525-32. PubMed ID: 11350666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV-1-infected children on HAART: immunologic features of three different levels of viral suppression.
    Zaccarelli-Filho CA; Ono E; Machado DM; Brunialti M; Succi RC; Salomão R; Kallás EG; de Moraes-Pinto MI
    Cytometry B Clin Cytom; 2007 Jan; 72(1):14-21. PubMed ID: 17041945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection.
    Oxenius A; Price DA; Günthard HF; Dawson SJ; Fagard C; Perrin L; Fischer M; Weber R; Plana M; García F; Hirschel B; McLean A; Phillips RE
    Proc Natl Acad Sci U S A; 2002 Oct; 99(21):13747-52. PubMed ID: 12370434
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Altered T cell differentiation associated with loss of CD27 and CD28 in HIV infected Indian individuals.
    Mojumdar K; Vajpayee M; Chauhan NK; Singh A; Singh R; Kurapati S
    Cytometry B Clin Cytom; 2012 Jan; 82(1):43-53. PubMed ID: 21695776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunophenotype of HIV+ patients during CD4 cell-monitored treatment interruption: role of the IL-7/IL-7 receptor system.
    Nemes E; Lugli E; Nasi M; Ferraresi R; Pinti M; Bugarini R; Borghi V; Prati F; Esposito R; Cossarizza A; Mussini C
    AIDS; 2006 Oct; 20(16):2021-32. PubMed ID: 17053348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterizing immune reconstitution after long-term highly active antiretroviral therapy in pediatric AIDS.
    Resino S; Correa R; Bellón JM; Sánchez-Ramón S; Muñoz-Fernández MA
    AIDS Res Hum Retroviruses; 2002 Dec; 18(18):1395-406. PubMed ID: 12487811
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children: analysis of cellular immune responses.
    Blazevic V; Jankelevich S; Steinberg SM; Jacobsen F; Yarchoan R; Shearer GM
    Clin Diagn Lab Immunol; 2001 Sep; 8(5):943-8. PubMed ID: 11527808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in levels of T cell subpopulations to monitor the response to antiretroviral therapy among HIV-1-infected patients during two years of HIV-1 replication suppression.
    Zhang JC; Zhang HJ; Li Y; Jing D; Liu Q; Zhao K; Liu QQ; Zhuang Y; Kang WZ; Sun YT
    Scand J Infect Dis; 2013 May; 45(5):368-77. PubMed ID: 23186319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dysregulation of CD28 and CTLA-4 expression by CD4 T cells from previously immunodeficient HIV-infected patients with sustained virological responses to highly active antiretroviral therapy.
    Stone SF; Price P; French MA
    HIV Med; 2005 Jul; 6(4):278-83. PubMed ID: 16011533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T cell responses to highly active antiretroviral therapy defined by chemokine receptors expression, cytokine production, T cell receptor repertoire and anti-HIV T-lymphocyte activity.
    Giovannetti A; Pierdominici M; Mazzetta F; Salemi S; Marziali M; Kuonen D; Iebba F; Lusi EA; Cossarizza A; Aiuti F
    Clin Exp Immunol; 2001 Apr; 124(1):21-31. PubMed ID: 11359439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Poor lymphoproliferative responses with low proportion of Gag-specific CD8 TEMRA cells in HIV-1-infected patients showing immunological and virological discordance despite prolonged suppression of plasma viremia.
    Sachdeva N; Weinstein JE; Ashman M; Sachdeva M; Brewer TH; Gracia D; Asthana D
    Viral Immunol; 2010 Feb; 23(1):49-61. PubMed ID: 20121402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Naive T-cell depletion related to infection by X4 human immunodeficiency virus type 1 in poor immunological responders to highly active antiretroviral therapy.
    Delobel P; Nugeyre MT; Cazabat M; Sandres-Sauné K; Pasquier C; Cuzin L; Marchou B; Massip P; Cheynier R; Barré-Sinoussi F; Izopet J; Israël N
    J Virol; 2006 Oct; 80(20):10229-36. PubMed ID: 17005700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppression of HIV replication in the resting CD4+ T cell reservoir by autologous CD8+ T cells: implications for the development of therapeutic strategies.
    Chun TW; Justement JS; Moir S; Hallahan CW; Ehler LA; Liu S; McLaughlin M; Dybul M; Mican JM; Fauci AS
    Proc Natl Acad Sci U S A; 2001 Jan; 98(1):253-8. PubMed ID: 11136258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Highly active antiretroviral therapy results in HIV type 1 suppression in lymph nodes, increased pools of naive T cells, decreased pools of activated T cells, and diminished frequencies of peripheral activated HIV type 1-specific CD8+ T cells.
    Gray CM; Lawrence J; Ranheim EA; Vierra M; Zupancic M; Winters M; Altman J; Montoya J; Zolopa A; Schapiro J; Haase AT; Merigan TC
    AIDS Res Hum Retroviruses; 2000 Sep; 16(14):1357-69. PubMed ID: 11018855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Central memory CD4 cells are an early indicator of immune reconstitution in HIV/AIDS patients with anti-retroviral treatment.
    Hua W; Jiao Y; Zhang H; Zhang T; Chen D; Zhang Y; Chen X; Wu H
    Immunol Invest; 2012; 41(1):1-14. PubMed ID: 21563924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Naïve T-cell dynamics in human immunodeficiency virus type 1 infection: effects of highly active antiretroviral therapy provide insights into the mechanisms of naive T-cell depletion.
    Di Mascio M; Sereti I; Matthews LT; Natarajan V; Adelsberger J; Lempicki R; Yoder C; Jones E; Chow C; Metcalf JA; Sidorov IA; Dimitrov DS; Polis MA; Kovacs JA
    J Virol; 2006 Mar; 80(6):2665-74. PubMed ID: 16501076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Specific patterns of CD4-associated immunosenescence in vertically HIV-infected subjects.
    Méndez-Lagares G; Díaz L; Correa-Rocha R; León Leal JA; Ferrando-Martínez S; Ruiz-Mateos E; Pozo-Balado MM; Gurbindo MD; de José MI; Muñoz-Fernández MA; Leal M; Pacheco YM
    Clin Microbiol Infect; 2013 Jun; 19(6):558-65. PubMed ID: 22735071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A pilot study to assess inflammatory biomarker changes when raltegravir is added to a virologically suppressive HAART regimen in HIV-1-infected patients with limited immunological responses.
    Lichtenstein KA; Armon C; Nagabhushanam V; Efaw BJ; Frazer-Abel A; Hiserote ME; Alam R
    Antivir Ther; 2012; 17(7):1301-9. PubMed ID: 22948290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects.
    Ortiz GM; Wellons M; Brancato J; Vo HT; Zinn RL; Clarkson DE; Van Loon K; Bonhoeffer S; Miralles GD; Montefiori D; Bartlett JA; Nixon DF
    Proc Natl Acad Sci U S A; 2001 Nov; 98(23):13288-93. PubMed ID: 11687611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.